Multimodal Assessment of Remodeling and Stratification in Heart Failure
Key facts
- Who runs it
- Shandong Provincial Hospital
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 1 Dec 2022
- Expected to end
- 10 Sept 2030
- Type of study
- Observational, 2 groups
- Record updated
- 17 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (6)Hide the full registry criteria
Who cannot take part
- myocarditis Inclusion Criteria: Male or female adults aged ≥18 years; diagnosis of myocarditis confirmed by at least one of the following: (a) cardiac magnetic resonance fulfilling the modified Lake Louise Criteria (at least one T2-based criterion for myocardial edema AND at least one T1-based criterion including native T1 mapping, extracellular volume, or late gadolinium enhancement in a non-ischemic distribution), OR (b) endomyocardial biopsy demonstrating histologic, immunologic, and immunohistochemical evidence of myocardial inflammation; OR (c) in patients with high clinical pretest probability, a combination of at least one clinical presentation (acute chest pain, dyspnea, palpitations, arrhythmia, syncope, or unexplained cardiogenic shock) AND at least one diagnostic finding (elevated cardiac troponin, ECG changes suggestive of myocardial injury, or echocardiographic evidence of new regional or global wall motion abnormality) AND CMR findings consistent with myocardial inflammation; time from symptom onset classified as acute (<4 weeks), subacute (4-12 weeks), or chronic (>3 months); for chronic myocarditis, persistent or recurrent symptoms or imaging evidence of ongoing myocardial inflammation for >3 months from initial onset; receiving standard clinical care, including guideline-directed medical therapy for heart failure when applicable; ability to provide written informed consent prior to any study-related assessment, or consent from a legally authorized representative if temporarily unable
- CAD: were the following: (1) age > 18 years; (2) CAD diagnosed according to current guidelines [10, 11]-(a) atleast 70% stenosis in one or more coronary arteries or > 50% stenosis of the left main stem in percutaneous coronary intervention (PCI) or computed tomography angiography (CTA); (b) history of severe angina or myocardial infarction (MI); (c) previous revascularization history, including surgical coronary artery bypass grafting (CABG).The exclusion criteria were the following: (1) definite non-ischemic heart disease; (2)acute MI; (3) any contraindication to CMR
- HCM Inclusion criteria: The diagnosis of hypertrophic cardiomyopathy is independently made by clinicians according to current guidelines, based on imaging examinations including CMR, electrocardiography, family history and genetic testing (if available). Inclusion criterion: left ventricular wall thickness ≥13 mm in ≥1 myocardial segment on CMR
- Chronic Heart Failure Inclusion criteria: age ≥18 years; established clinical diagnosis of chronic heart failure for at least 3 months based on current guideline criteria; NYHA class I-IV; LVEF assessed within 12 months by echocardiography, CMR, or other validated imaging, meeting HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), or HFpEF (LVEF ≥50%); for HFpEF, at least one supportive finding documented within 12 months (elevated NT-proBNP >125 pg/mL or BNP >35 pg/mL, structural heart disease such as left atrial enlargement, left ventricular hypertrophy, or diastolic dysfunction, or prior heart failure hospitalization); stable clinical condition with no change in NYHA class or heart failure-specific therapy within 7 days before enrollment; receiving guideline-directed medical therapy at a stable dose for at least 4 weeks unless contraindicated or not tolerated; ability to provide written informed consent Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging
- Acute decompensated heart failure Inclusion criteria: male or female adults aged ≥18 years; current hospitalization or unscheduled clinic/emergency department visit for a primary diagnosis of acute decompensated heart failure (de novo or decompensation of chronic heart failure) regardless of LVEF category (HFrEF, HFmrEF, or HFpEF); at least one clinical sign of volume overload (peripheral edema score ≥2, pulmonary congestion or pleural effusion on chest X-ray or ultrasound, ascites on ultrasound, or elevated jugular venous pressure); elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP >250 pg/mL); receiving or anticipated to receive intravenous diuretic therapy during the index hospitalization or acute care episode; for HFpEF, diagnosis supported by structural heart disease and/or diastolic dysfunction plus elevated natriuretic peptides; ability to provide written informed consent or consent from a legally authorized representative if temporarily unable. Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging
Other criteria
- Dilated Cardiomyopathy Inclusion criteria: Diagnosed dilated cardiomyopathy (DCM) according to the World Health Organization / International Society and Federation of Cardiology (WHO/ISFC) criteria, characterized by elevated body surface area-indexed left ventricular end-diastolic volume and left ventricular ejection fraction (LVEF) below published age- and sex-specific reference values
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Heart failure is a common condition in which the heart cannot pump blood effectively. It can be caused by reduced blood supply to the heart (ischemic) or by other causes (nonischemic), and it may begin suddenly (acute) or last for a long time (chronic). Heart failure can lead to changes in the heart's structure and function, called cardiac remodeling, and to different risks of hospitalization or death.
Read full original descriptionShow less
This is a prospective, multicenter, observational study. It will enroll adults with acute or chronic heart failure, including both ischemic and nonischemic types. Participants will receive their usual medical care and will undergo multimodal assessments. These may include cardiac magnetic resonance imaging, echocardiography, electrocardiography, blood tests, and computed tomography, including high-resolution coronary CT or photon-counting CT when available. Data on heart structure, function, blood flow, tissue characteristics, and clinical outcomes will be collected during follow-up.
The main goals are to better understand cardiac remodeling in different types of heart failure and to find out whether combining information from different tests can improve risk stratification. Advanced statistical methods and artificial intelligence will be explored as part of the analysis, but artificial intelligence is not the main focus; the study aims to integrate all data sources in a balanced way. No new drug or device will be tested. The results may help doctors improve how they evaluate and monitor patients with heart failure.
The 2 groups in the trial
- Patient group
Participants enrolled who meet the diagnostic criteria according to clinical guidelines and the inclusion and exclusion criteria
- Healthy volunteers
Healthy volunteer group matched with the patient group for age and sex
Next steps
For your doctor
Doctor ask sheet
A PDF summary of this trial for your doctor: what it tests, who can take part, its registry number and links, with room for notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Artificial Intelligence-Enhanced Multimodal Cardiovascular Phenotyping for Cardiac Remodeling and Risk Stratification in Ischemic and Nonischemic Acute and Chronic Heart Failure: A Prospective, Multicenter, Observational Cohort Study
- Record updated
- 17 November 2026